Literatur
-
1
Goebel F D, Walli R.
Metabolische Komplikationen
der antiretroviralen Therapie der HIV-Infektion.
Dtsch
Med Wschr.
2000;
125
771-773
-
2
Segerer S, Bogner J R, Walli R, Loch O, Goebel F D.
Hyperlipidemia
under therapy with protease inhibitors.
Infection.
1999;
27
77-81
-
3
Penzak S R, Chuck S K.
Hyperlipidemia
associated with HIV protease inhibitor use: pathophysiology, prevalence,
risk factors and treatment.
Scand J Inf Dis.
2000;
32
111-123
-
4 Klein D, Sidney S, Hurley L, Iribarren C. Do protease inhibitors
increase the risk for coronary heart disease among HIV positive
patients?. Presented at: 6th Conference of
Retroviruses and Opportunistic Infections; January 31-February 4,
Chicago, IL. Abstract 657 1999
-
5 Coplan P, Nikas A, Saah A, Nessly M, Doll L, Leavitt R. et al .No association observed between indinavir
therapy for HIV-AIDS and myocardial infarction in 4 clinical trials
with 2.825 subjects. Presented at: 6th Conference
of Retroviruses and Opportunistic Infections; January 31-February
4, Chicago, IL. Abstract 658 1999
-
6
Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swenson L. et al .
Severe premature coronary artery disease
with protease inhibitors (letter).
Lancet.
1998;
351
1328
-
7
Flynn T N, Bricker L A.
Myocardial
infarctions in HIV-infected men receiving protease inhibitors (letter).
Ann
Intern Med.
1999;
131
548
Dr. med. Christian A. Koch
Dr. med. Gernot Wolkersdoerfer
National Institutes of Health, NICHD
Building 10, Rm 9D42
Phone: 001/301/402-4620
Fax: 001/301/402-0180
Email: kochc@exchange.nih.gov
